Cardima Preparing For Pivotal AF Trials Of Revelation Ablation Catheter
This article was originally published in The Gray Sheet
Executive SummaryCardima will begin a 60-100 patient, 10-center pivotal atrial fibrillation trial of its Revelation cardiac ablation microcatheter pending FDA approval of the company's feasibility trial, according to an Oct. 23 release.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.